Cetera Trust Company’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$8.11K Sell
130
-200
-61% -$12.6K ﹤0.01% 300
2026
Q2
$19K Hold
330
– – 0.01% 259
2026
Q1
$20K Hold
330
– – 0.01% 255
2025
Q4
$17.8K Hold
330
– – 0.01% 259
2025
Q3
$14.9K Hold
330
– – 0.01% 265
2025
Q2
$15.3K Hold
330
– – 0.01% 262
2025
Q1
$20.1K Sell
330
-1,550
-82% -$90.3K 0.01% 252
2024
Q4
$106K Sell
1,880
-88
-4% -$4.92K 0.07% 195
2024
Q3
$102K Sell
1,968
-15,959
-89% -$749K 0.06% 205
2024
Q2
$745K Sell
17,927
-2,165
-11% -$96.9K 0.47% 50
2024
Q1
$1.09M Buy
20,092
+2,325
+13% +$118K 0.66% 42
2023
Q4
$912K Buy
+17,767
New +$933K 0.57% 44

Other funds holding BMY

Cetera Trust Company's BMY Position: Q3 2026 in Review

Cetera Trust Company reduced its Bristol-Myers Squibb (BMY) stake by 61% in Q3 2026, selling an estimated $12.6K and leaving 130 shares worth $8.11K. The position accounts for ﹤0.01% of the portfolio, ranked #300.

Cetera Trust Company first reported a position in BMY in Q4 2023 and has held it in 12 quarters since. The position peaked at $1.09M in Q1 2024. 2,553 funds tracked by Wall St. Rank hold BMY as of Q3 2026.

  • Cetera Trust Company held 130 shares of Bristol-Myers Squibb worth $8.11K as of Q3 2026.
  • Cetera Trust Company sold 200 Bristol-Myers Squibb shares in Q3 2026, an estimated $12.6K.
  • Bristol-Myers Squibb made up ﹤0.01% of Cetera Trust Company's portfolio in Q3 2026, its #300 holding.
  • Cetera Trust Company first reported a position in Bristol-Myers Squibb in Q4 2023 and has held it in 12 quarters since.
  • Cetera Trust Company's Bristol-Myers Squibb position peaked at $1.09M in Q1 2024.
  • 2,553 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q3 2026.

Based on Cetera Trust Company's 13F filing for Q3 2026, filed 9 Nov 2026.